Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR – Get Rating) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 7,900 shares, a decline of 18.6% from the April 15th total of 9,700 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 10,600 shares, the days-to-cover ratio is currently 0.7 days.
NASDAQ EUCR remained flat at $$9.88 on Tuesday. The company had a trading volume of 53 shares, compared to its average volume of 12,059. Eucrates Biomedical Acquisition has a fifty-two week low of $9.65 and a fifty-two week high of $10.77. The company has a 50 day moving average of $9.86 and a 200 day moving average of $9.83.
A number of large investors have recently bought and sold shares of EUCR. Deerfield Management Company L.P. Series C acquired a new position in Eucrates Biomedical Acquisition in the fourth quarter valued at about $9,760,000. Goldman Sachs Group Inc. grew its stake in Eucrates Biomedical Acquisition by 1,476.7% in the first quarter. Goldman Sachs Group Inc. now owns 553,622 shares of the company’s stock valued at $5,448,000 after acquiring an additional 518,510 shares during the period. D. E. Shaw & Co. Inc. boosted its position in shares of Eucrates Biomedical Acquisition by 172.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 478,669 shares of the company’s stock worth $4,672,000 after buying an additional 302,988 shares during the period. Eisler Capital UK Ltd. acquired a new position in shares of Eucrates Biomedical Acquisition during the fourth quarter worth about $2,269,000. Finally, Saba Capital Management L.P. boosted its position in shares of Eucrates Biomedical Acquisition by 379.6% during the first quarter. Saba Capital Management L.P. now owns 270,751 shares of the company’s stock worth $2,670,000 after buying an additional 214,300 shares during the period. 54.48% of the stock is owned by hedge funds and other institutional investors.
Eucrates Biomedical Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
- Get a free copy of the StockNews.com research report on Eucrates Biomedical Acquisition (EUCR)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
- Time to Ride These 3 Mid Cap Momentum Plays
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 "MUST OWN" Growth Stocks
Receive News & Ratings for Eucrates Biomedical Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eucrates Biomedical Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.